JP2006151999A5 - - Google Patents

Download PDF

Info

Publication number
JP2006151999A5
JP2006151999A5 JP2006055107A JP2006055107A JP2006151999A5 JP 2006151999 A5 JP2006151999 A5 JP 2006151999A5 JP 2006055107 A JP2006055107 A JP 2006055107A JP 2006055107 A JP2006055107 A JP 2006055107A JP 2006151999 A5 JP2006151999 A5 JP 2006151999A5
Authority
JP
Japan
Prior art keywords
crystal
tautomer
solvate
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006055107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006151999A (ja
JP4504323B2 (ja
Filing date
Publication date
Priority claimed from GBGB9713730.1A external-priority patent/GB9713730D0/en
Application filed filed Critical
Publication of JP2006151999A publication Critical patent/JP2006151999A/ja
Publication of JP2006151999A5 publication Critical patent/JP2006151999A5/ja
Application granted granted Critical
Publication of JP4504323B2 publication Critical patent/JP4504323B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006055107A 1997-06-30 2006-03-01 結晶性マクロライドおよびその調製方法 Expired - Lifetime JP4504323B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713730.1A GB9713730D0 (en) 1997-06-30 1997-06-30 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP50628799A Division JP3880634B2 (ja) 1997-06-30 1998-06-26 結晶性マクロライドおよびその調製方法

Publications (3)

Publication Number Publication Date
JP2006151999A JP2006151999A (ja) 2006-06-15
JP2006151999A5 true JP2006151999A5 (enExample) 2006-12-07
JP4504323B2 JP4504323B2 (ja) 2010-07-14

Family

ID=10815103

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50628799A Expired - Lifetime JP3880634B2 (ja) 1997-06-30 1998-06-26 結晶性マクロライドおよびその調製方法
JP2006055107A Expired - Lifetime JP4504323B2 (ja) 1997-06-30 2006-03-01 結晶性マクロライドおよびその調製方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP50628799A Expired - Lifetime JP3880634B2 (ja) 1997-06-30 1998-06-26 結晶性マクロライドおよびその調製方法

Country Status (31)

Country Link
US (1) US6423722B1 (enExample)
EP (1) EP0994880B1 (enExample)
JP (2) JP3880634B2 (enExample)
KR (1) KR100399765B1 (enExample)
CN (1) CN1139595C (enExample)
AR (1) AR017754A1 (enExample)
AT (1) ATE287410T1 (enExample)
AU (1) AU739211B2 (enExample)
BR (1) BR9810956A (enExample)
CA (1) CA2290412C (enExample)
CO (1) CO4940463A1 (enExample)
CZ (1) CZ297244B6 (enExample)
DE (1) DE69828692T2 (enExample)
DK (1) DK0994880T3 (enExample)
ES (1) ES2236922T3 (enExample)
GB (1) GB9713730D0 (enExample)
HU (1) HU227755B1 (enExample)
ID (1) ID24897A (enExample)
IL (1) IL132761A0 (enExample)
MY (1) MY118718A (enExample)
NO (1) NO312765B1 (enExample)
NZ (1) NZ500994A (enExample)
PE (1) PE97699A1 (enExample)
PL (1) PL192761B1 (enExample)
PT (1) PT994880E (enExample)
RU (1) RU2219181C2 (enExample)
SK (1) SK285665B6 (enExample)
TR (1) TR199903189T2 (enExample)
TW (1) TW552264B (enExample)
WO (1) WO1999001458A1 (enExample)
ZA (1) ZA985655B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
ATE450535T1 (de) * 2003-09-03 2009-12-15 Glaxo Group Ltd Neues verfahren zur herstellung von pleuromutilinderivaten
BRPI0509708B8 (pt) * 2004-04-08 2021-05-25 Meda Pharma S A R L espuma farmacêutica, composição de espuma de pimecrolimus contendo glicol de hexileno, opcionalmente álcool de oleil, dimetilisosorbídeo e/ou triglicerídeos de cadeia média e uso
WO2006060616A1 (en) * 2004-12-01 2006-06-08 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Processes for producing crystalline macrolides
WO2008057511A2 (en) * 2006-11-06 2008-05-15 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
JP2010512333A (ja) * 2006-12-07 2010-04-22 ヘルシン ヘルスケア ソシエテ アノニム 塩酸パロノセトロンの結晶及び非晶質形
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US10369256B2 (en) 2009-07-10 2019-08-06 Boston Scientific Scimed, Inc. Use of nanocrystals for drug delivery from a balloon
WO2011008393A2 (en) 2009-07-17 2011-01-20 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013022458A1 (en) * 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
EP2972258B1 (en) 2013-03-15 2021-08-04 Biosensors International Group, Ltd. Purification of rapamycin derivatives
EP3178824A1 (en) 2015-12-08 2017-06-14 Medichem, S.A. Process for preparing pimecrolimus
US10975097B2 (en) * 2017-05-01 2021-04-13 Meda Ab Process to convert technical ascomycin into purified pimecrolimus
EP3741367A1 (en) 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease
WO2024209038A1 (en) 2023-04-06 2024-10-10 Premark Pharma Gmbh Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
CY1306A (en) 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
JP2728482B2 (ja) * 1989-01-26 1998-03-18 協和醗酵工業株式会社 マクロライド系抗生物質の精製法
EP0433428B1 (en) 1989-07-10 1994-10-12 Chemferm V.O.F. A stable form of cephradine, process for its production and intermediates used therein
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
WO1991013889A1 (en) * 1990-03-13 1991-09-19 Fisons Plc Immunosuppressive macrocyclic compounds
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
EP0480623A1 (en) * 1990-10-11 1992-04-15 Merck & Co. Inc. New halomacrolides and derivatives having immunosuppressive activity
DK0526171T3 (da) 1991-07-30 1997-08-25 Ajinomoto Kk Krystaller af N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanin og fremgangsmåder til fremstilling deraf
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
JP3808500B2 (ja) * 1994-02-22 2006-08-09 キューレータズ オブ ディ ユニバーシティ オブ ミズーリ 分離剤としての大環状抗生物質
WO1997008182A1 (en) * 1995-08-24 1997-03-06 Merck & Co., Inc. Process for the preparation of imidazolyl macrolide immunosuppressants
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2006151999A5 (enExample)
CN103261187B (zh) 制备四唑取代的邻氨基苯甲酰胺衍生物的方法以及这些衍生物的晶体多形体
JP2020518662A (ja) 化合物の結晶多形、その製造方法及び用途
JP2011506374A (ja) テノホビルジソプロキシルの固形物
CA2572147A1 (en) Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
JP2020517611A5 (enExample)
CN103951634B (zh) 一种依帕司他结晶盐水合物和羟基哌啶共晶物及其制备方法和应用
JP2014500357A5 (enExample)
JP2016537346A5 (enExample)
JP2015508092A5 (enExample)
RS61986B1 (sr) Hemisulfat so 5,10-metilen-(6)-tetrahidrofolne kiseline
HRP20251307T1 (hr) Kristalni oblik trietilentetramin tetrahidroklorida i njegova farmaceutska upotreba
KR102878525B1 (ko) 피리미디닐아미노-피라졸 화합물의 다형체와 고체 형태, 그리고 생산 방법
JP2021501127A5 (enExample)
JP2016510768A5 (enExample)
RU2016106125A (ru) Соли дасатиниба в кристаллической форме
JP2009040767A5 (enExample)
CN102807575B (zh) 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用
JP2012512145A (ja) フリバンセリンの結晶性の塩形態
CN103965116A (zh) 半5-氟胞嘧啶盐、其制备方法及应用
JP2013541589A5 (enExample)
JP2019529553A5 (enExample)
CN107033094A (zh) 一种药物共晶的晶型及其制备方法和组合物
JP2016527227A (ja) ペメトレキセドトロメタミン塩の新規な結晶形
JP2020503330A5 (enExample)